INVEST IN EVA MEDTEC TODAY!

Automated Lymphatic Therapy (ALT) Technology

Eva Medtec is a medical technology enterprise that launched commercially in 2021 with its flagship product, the Neuroglide™, and has raised $3.7M to date.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Eva Medtec

$92,913.52 Raised

REASONS TO INVEST

Reasons Icon

The Neuroglide™ by Eva Medtec makes it possible for anyone to experience the benefits of automated lymphatic therapy with one simple, at-home system. The company’s proprietary technology has received FDA-clearance for pain relief and increased circulation, which has numerous physical health benefits.

Reasons Icon

By developing non-invasive solutions that can be accessed without the need for a prescription, Eva Medtec is targeting the $4B Pain Management Devices market, which is expected to reach more than $8.5B by 2030 (8.5% CAGR). With additional therapy attachments currently in development, Eva Medtec also plans to address the $18.6B Stress Management Market as well as the $30B+ Sleep Health Market as the company looks to expand the Neuroglide’s FDA labeling.*

Reasons Icon

At the helm of Eva Medtec’s operations is a team of passionate founders with decades of combined medical and marketing experience seeking to continually evolve the company’s product pipeline with new innovations for the med-tech market. All products developed by Eva Medtec are based on extensive in-field expertise and are made in the U.S. by a full, in-house manufacturer.

*Market information provided by Precedence Research, Globe Newswire, and McKinsey & Company (source, source, source)





the pitch

Eva Medtec is the creator and manufacturer of Neuroglide™, an over-the-counter, FDA-cleared medical device engineered to automate and emulate manual lymphatic drainage (MLD) therapy. Lymphatic fluid carries toxins and other debri from cells of the body. When this fluid builds up in the lymphatic vessels, the body can have a number of negative reactions, including swelling and discomfort. MLD therapy seeks to accelerate lymph flow and decongest the body’s soft tissues of excess lymph, a practice with many associated health benefits – including pain management, improved rest, relaxation, and recovery. 




Holistic Methodology Meets Modern Innovation

The Neuroglide™ is a back and neck device that emulates the precise pressure profiles and principles of manual lymphatic drainage (MLD) therapy in order to make this highly-specialized modality more available and accessible to all.



The technology was developed with the expertise of a certified MLD therapist, Eva Medtec's Founder & CTO, Irene Waldridge. Irene previously founded a publicly traded, market-leading lymphedema company, Tactile Medical (NASDAQ: TCMD), which at one point held a $1.2B market cap.* Irene’s experience practicing the techniques of MLD led her to witness its many health benefits firsthand. Because lymphatic therapy supports the body’s immune and autonomic nervous systems, MLD treatment has the potential to improve patient outcomes in cases of acute pain, injury, chronic pain, and other chronic conditions.

*Eva Medtec's leadership experience is not a guarantee of future performance or success.

The Problem & Our Solution


Bringing Together Technique and Technology to Provide Therapeutic At-Home Care

In recent years, more medical and therapeutic professionals have begun to recognize the body’s lymphatic system as having an important impact on overall health and wellness. Increased lymph circulation is linked to improved immune function, as well as reduction of swelling, congestion, and inflammation. However, because MLD therapy is an advanced modality available only through a handful of certified professional practitioners, most people aren’t able to access lymphatic therapy as often as needed for it to be truly effective.


(source)


Understanding this, Eva Medtec sought to develop a fully-automated device that can be used from the comfort of home, capable of producing benefits similar to receiving hands-on treatment. Utilizing an array of air channels that inflate and deflate in sequence, the Neuroglide™ is able to emulate the proper pressure, tempo, and mechanics needed to access the lymphatic system, promoting healthy flow of lymph throughout the entire body. This technology has been cleared by the FDA for pain relief and increased circulation, and is easy to use, anywhere, at any time.

The Market & Our Traction


Backed by Science and Built to Serve Multiple Market Verticals

In order to introduce the Neuroglide™ to the commercial market, Eva Medtec has obtained Class II FDA clearance for pain relief and increased circulation, as well as utility patent status for our proprietary technology. With these proof-positive elements in place, the company has been able to generate our first $100K in sales.



In pilot clinical patient trials, users of Neuroglide™ reported reduced back and neck pain, more restorative and consistent sleep, improved athletic recovery, and reduced pain from fibromyalgia. 



As Eva Medtec works to expand awareness and accessibility to MLD therapy, the company is equally as excited about the planned, future therapy devices currently in development. These devices are designed for use with specific body regions such as the knee, lower legs, lumbar, and head, and work with the Neuroglide’s Controller Unit at launch. In addition to further developing the company’s product line, Eva Medtec also plans to expand Neuroglide’s FDA labeling into other benefit cases such as improved sleep, stress reduction, and athletic recovery.

Why Invest


Trusted Technology on Trend to Provide Positive Impact

As lymphatic therapies and MLD continue to generate a buzz in the medical sector as well as amongst A-list celebrities, such as Jennifer Aniston, the Kardashians, and Ariana Grande, Eva Medtec anticipates a growing trend of consumers looking to experience its many health benefits for themselves. Even so, because MLD remains a niche modality available only to a limited market, the company expects automated devices such as the Neuroglide™ have great potential to be widely embraced by at-home consumers


With support from funding, Eva Medtec is poised for expansion and looks forward to offering an affordable, accessible solution that improves people’s daily lives. Be a part of Eva Medtec's mission by investing today!



Neuroglide™ is a Class II, over-the-counter FDA cleared medical device intended for the temporary relief of minor muscle aches and pains and for the temporary increase in circulation to the treated areas.

Code View

ABOUT

HEADQUARTERS

6300 W. Old Shakopee Road, Ste 140
Bloomington, MN 55438
VALUATION

$11.03M

Eva Medtec is a medical technology enterprise that launched commercially in 2021 with its flagship product, the Neuroglide™, and has raised $3.7M to date.

TEAM

John Foster Dinusson
John Foster Dinusson
President & CEO

John was the Founder and President of OrthoCor Medical, which was acquired by Caerus Crop. He brings over 25 years of leadership in diverse areas, including venture capital, finance and operations. John’s primary experience was at Blumberg Capital, an early-stage venture capital firm that specializes in leading Seed and Series A rounds in syndication with angels, venture capital firms and strategic investors. John led Initiative Ventures where he worked with early stage Minnesota based ventures. He has worked with many successful start-up companies in obtaining financing and in their growth efforts. He currently works in an advisory capacity with several early stage companies.

Irene Anne Waldridge
Irene Anne Waldridge
Founder/CTO

Irene Waldridge, Founder & CTO. Irene Waldridge is a seasoned executive and entrepreneur with over 27 years inventing medical devices. She is the Founder of two companies, Tactile Medical and Eva Medtec. At Tactile Medical, Irene invented and developed the Flexitouch device for treating lymphedema and venous insufficiency. She has held a variety of executive positions, including CEO, Chairman of the Board and CTO. She is also the inventor of the FDA-cleared, OTC, Neuroglide™ Pain Relief and Recovery System to help patients with acute/chronic pain, and increase lymphatic circulation for the removal of harmful cellular waste from the body's soft tissues. 

David Edward Rupp
David Edward Rupp
VP of Marketing

Mr. Rupp spent 15+ years as a National Marketing Manager where he planned, created, and directed the department’s strategic plan and oversaw planning and implementation of 5 national product lines that saw company wide sales more than triple in 4 years.

Toni May Hastings
Toni May Hastings
VP of Administration

20 years of experience working with pain management clinics, and 5 years of experience with Class II medical devices, R&D and manufacturing/operations.

Mark Melin, MD

Mark Melin, MD

Medical Director

M. Mark Melin MD FACS RPVI FACCWS, is a surgeon and Medical Director of the M Health Wound Healing Institute (South Campus) and an Adjunct Associate Professor in the University of Minnesota Surgical Department. His interests and educational niches include management of lymphedema/lymphatic stasis in the wounded patient, the endothelial glycocalyx, adjunctive micronutrient and bionutrient application to wound care, diosmin Micronized Purified Flavonoid Fraction (MPFF), polygenic abnormality impact upon wound resolution, wound pH and biofilm management, and emerging technologies in wound products and wound technologies.

Dan Sipple, DO

Dan Sipple, DO

Medical Advisor

Dr. Daniel Sipple is board certified in physical medicine and rehabilitation with sub-specialty board certification in pain medicine. He trained at the Rehabilitation Institute of Chicago, now the Shirley Ryan Ability Lab, the #1 rated rehabilitation hospital in US News and World Report over 20 years running. He served on faculty at Northwestern University Medical School while working at RIC’s American Academy of Pain Medicine Center of Excellence. He subsequently practiced in Denver Colorado for two years, working along side former team physicians of the Denver Broncos and Colorado Rockies. Thereafter, at the Mayo Clinic in Eau Claire, Wisconsin via the Pain Clinic of NW Wisconsin. He served as the medical director the Health East Spine Center, and service line medical director over Neurosurgery, Behavioral Health, Pain and Spine for the health system. Dr. Sipple is the co-founder of InSitu Biologics, and co-inventor of INSB 200, sustained release non-opiate pain killer for post operative pain set to enter phase I FDA clinical trials in 2022. He is the patent holder in safe needle technology and the founder of Acies Medical. He served on the Board of Directors for the Society for Brain Mapping and Therapeutics, a NASA Spinout, and part of President Obama’s BRAIN Initiative.

Doug Goldstein, DPT

Doug Goldstein, DPT

Medical Advisor

Doug earned his Doctorate in Physical Therapy from The University of Colorado School of Medicine – Physical Therapy Program. His primary focus is in orthopedics where he is both board certified and fellowship trained. His specialization is performance enhancement and advises athletes from the NFL, NBA, USA Men’s/Women’s Soccer, MLS, MLB, UFC, USA Track and Field. He most recently founded Launchpad Fitness which utilizes AI computer vision to provide youth athletes performance training.

TERMS

Eva Medtec
Overview
PRICE PER SHARE
$1.49
DEADLINE
Mar 21, 2023
VALUATION
$11.03M
AMOUNT RAISED
$92,913.52
Breakdown
MIN INVESTMENT
$299.49
MAX INVESTMENT
$1,234,999.91
MIN NUMBER OF SHARES OFFERED
6,711
OFFERING TYPE
Equity
ASSET TYPE
COMMON
SHARES OFFERED
Common Stock
MAX NUMBER OF SHARES OFFERED
828,859

Maximum Number of Shares Offered subject to adjustment for bonus shares


Company

:

Eva Medtec, Inc.

Corporate Address

:

6300 W. Old Shakopee Road, Ste 140, Bloomington, MN 55438

Offering Minimum

:

$9,999.39

Offering Maximum

:

$1,234,999.91

Minimum Investment Amount

(per investor)

:

$299.49











Terms


Offering Type

:

Equity

Security Name

:

Common Stock

Minimum Number of Shares Offered

:

6,711

Maximum Number of Shares Offered

:

828,859

Price per Share

:

$1.49

Pre-Money Valuation

:

$11,026,421.67











*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Time-Based:

Friends & Family Bonus

Invest within the first 48 hours and receive 20% bonus shares. 

Super Early Bird Bonus

Invest within the first week and receive 10% bonus shares.

Early Bird Bonus

Invest within the first two weeks and receive 5% bonus shares.

Amount-Based:

$700

Invest $700 and receive 2% bonus shares. 

$1,500+ | Tier 1

Invest $1,500 and receive 4% bonus shares. 

$5,000+ | Tier 2

Invest $5,000 and receive 7% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)  

$10,000+ | Tier 3

Invest $10,000 and receive 15% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD) 

$25,000+ | Tier 4

Invest $25,000 and receive 20% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD) 

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Eva Medtec, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class B Non-Voting Common Stock at $3.20/share, you will receive 10 additional shares of Non-Voting Common Stock, meaning you'll own 110 shares for $320. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Inter company debt or back payments.

PRESS

Article Image
WSJ

https://www.wsj.com/articles/hailey-bieber-lymphatic-massage-rebecca-faria-11653493010

ALL UPDATES

01.26.23

We are excited to disrupt the Manual Lymphatic Drainage (MLD) market like never before!


Amazing News! Manual Lymphatic (MLD) therapists, physicians and patients are so amazed to see neck/back pain relief and improved circulation, many of them are investing in Eva Medtec.

 

We are so excited to share with you the Neuroglide’s automated MLD technology has been proving its value in treating patients in hospitals, clinics, and at-home.

 

We are grateful to see new and returning investors! Are you ready to join them? The minimum to invest is just $299.49.

 

 

– Eva Medtec

                           

01.19.23

Meet Our President and Chief Executive Officer!

A person smiling in front of a purple background

Description automatically generated with medium confidence


My Passion Is Delivering Extraordinary Results!


For over 25+ years, I have been an entrepreneur and Executive Leader in Medical Devices delivering extraordinary results.

 

My background with fundraising, strategic planning, business development, and commercialization drives results in growth, revenue, operational performance, and profitability through innovative commercial strategies and highly successful product launches.

 

My next-generation leadership through coaching and accountability, strong ethics, intellectual curiosity, passion, and commitment help improve lives. My collaborative and transformational leadership will add strength to our vision and mission at Eva Medtec.

 

As an adjunct faculty member for the University of Minnesota, I taught graduate classes in the School of Engineering and the Medical Device Innovation Program. My experience developing drug-free, non-invasive, and mobile medical technology, helps patients manage pain, regain physical function, and contribute to an active lifestyle.

 

As the founder, President and CEO of OrthoCor Medical, we developed of drug-free, non-invasive, and mobile medical technology, using pulsed electromagnetic field (PEMF) technology to help patients manage pain, regain physical function, and contribute to an active lifestyle. I raised $6.5M in equity financing and built the company from inception to exceptional YoY revenue growth. I helped secure four FDA clearances, and collaborated with Q&A, R&D, and manufacturing to launch nine next-generation products.


 My Personal Interests

I studied a year abroad in Nepal, Tibet, and India, co-produced an internationally televised Tibetan Freedom Concert that raised over $1M, and served in the U.S. House of Representatives Congressional Page School my junior year of high school.

 

 

Best Regards,             

John Dinusson

President and CEO                           

01.13.23

Meet the Founder of Eva Medtec!

Graphical user interface, application

Description automatically generated 

Ms. Irene Waldridge pushes through all challenges and obstacles
 to help improve patients’ quality of life.

 

Our founder and Chief Technology Officer, Irene Waldridge, is a certified massage and lymphatic drainage (MLD) therapist. She has 27 years of experience inventing, developing, and marketing automated Lymphatic Therapy (ALT) medical devices. She is the founder of two medical device companies, Eva Medtec and Tactile Medical.

After receiving her MLD training on the anatomy and physiology of the lymphatic system, Ms. Waldridge embarked on a lifelong pursuit of engineering devices that automate MLD therapy. Her deep desire is to improve the quality of peoples’ lives by treating lymphedema, venous insufficiency, relieving pain, improving lymphatic circulation and improving sleep recovery.

 

Tactile Medical

Ms. Waldridge founded Tactile Medical, a public company with a market value of $1.3 billion prior to COVID. At Tactile, Irene’s dedication to advancing the standard of care for treating lymphedema and vascular diseases at-home became a reality. She invented the innovative Flexitouch® system, which has helped over 100,000 patients.

 

Eva Medtec, Inc.

Irene is the inventor of the Neuroglide™ system, an over-the-counter, FDA-cleared medical device that automates MLD therapy for the treatment of neck/back pain and increased circulation. Her commitment to relieving pain, and increasing lymphatic circulation will lead to other treatments such as post-op swelling (edema), injuries, lymphedema, and improving sleep.

 

If you would like to speak to Irene directly, you may call 612-251-3949 or email her at iwaldridge@evemedtec.com

 

 

Best Regards,

                

John Dinusson

President and CEO                                                           

01.11.23

Learn more about Eva Medtec’s pilot sleep study.

A person lying on a bed

Description automatically generated with medium confidence

Pain Management Device Market

The 2021 US Sleep Device Market was estimated at $15 billion and is expected to increase to $67.7 billion in 2030 with a CAGR of 18.1%. Painful neck and back problems are pervasive and associated with chronic pain, disability and high healthcare utilization. 

Chronic Pain Affects Sleep Quality – Doug Goldstein, Doctor of Physical
 Therapy (DPT)

Eva Medtec Medical Advisor, Doug Goldstein, conducted a pilot sleep study to determine what effect the Neuroglide™ system has on sleep recovery. Participants used a wearable device validated for measuring heart rate variability, resting heart rate, strain, and REM/deep sleep. The study was designed to measure sleep biometrics for a total of 14 days. A 7-day baseline pretest without using Neuroglide, followed by a 7-day test period using the Neuroglide for half hour prior to their regular sleep period. The results of this study revealed an improvement in recovery (+14.6% for test period as a group), with an increase in HRV as well as Deep and REM sleep overall. This study indicates the Neuroglide system increases a person’s parasympathetic (rest and digest) response and may help promote relaxation that can lead to improved sleep and/or recovery. 

 

Best Regards,              

John Dinusson

President and CEO                           

01.09.23

Why Neuroglide plays an important part in solving the challenges of treating chronic neck and back pain.

Recently, the company’s Medical Director, Dr. Mark Melin, MD, submitted an Abstract Poster on MLD and pain at the 2022 American Vein & Lymphatic Society (AVSL) in New Orleans. We are pleased to announce that he won the First Abstract Poster Award! (Note: Neuroglide is based on the principles of MLD therapy to make it possible for anyone to get the benefits of Automated Lymphatic Therapy (ALT) with one simple, at-home system.)

However, this poster presentation is just one of the many positive and important activities we have planned for 2023. Dr. Melin continues to work on exciting scientific supporting data that we expect will show movement of stagnant lymph that may harbor inflammatory cytokines. We will conduct further studies showing how the Neuroglide system alleviates neck and back-paraspinal pain and potentially improve axillary and inguinal lymphatic functionality. 

In addition, we are excited to share with you one of the many patient testimonials to come to us in 2022. A Physical Therapist/MLD therapist using Neuroglide had this to say: “This is GREAT!!! I am a believer too. I have been sleeping well and truthfully for 2 weeks now I am not having anxiety attacks at night. They come on from pain in the neck and upper back. They were nightly and now I have had just one since doing this (Neuroglide) one hour each night before bed. Great stuff.”

We have many other Neuroglide success stories to share with you in upcoming communications, so keep an eye out for these interesting and sometimes incredible patient experiences.

We are excited about our StartEngine investment momentum. 2023 will be our best year yet, thanks to your belief and support. We can't wait to keep growing and sharing our successes with you.

 

Best Regards,                        

John Dinusson

President and CEO                                                                           

01.04.23

We are Working Hard to Build Momentum in 2023!

" If it weren’t hard, everyone would do it. It's the hard that makes it great.” - Tom Hanks
 

At Eva Medtec, we are working hard to give all of our investors the fruits of our labor. We don’t take the path of least resistance. We work hard to make things happen for the larger reward in the future.

What makes Eva Medtec’s Neuroglide stand apart from other forms of pain management therapy devices is our dedicated focus on designing products that are truly safe, effective and that will change the quality of lives of people who need it. Our approach is allowing MLD therapists to use the Neuroglide in their clinics and refer their patients to us, as well as pain management physicians to recommend Neuroglide for their back and neck pain injury patients.

Neuroglide has already attracted the attention of physicians and MLD therapists. There’s no doubt our word-of-mouth advertising is making an enormous difference. These healthcare professionals can’t wait to recommend the Neuroglide after their patients try it for 30-minutes and they see and feel the amazing results. As we continue to raise funds and hire a salesperson, we expect greater momentum in 2023! 

Other good news, in early 2023, we expect to receive a second patent on our unique, advanced Valve Module Technology that is used to manage the therapeutic inflation and deflation of each Neuroglide air channel. This technology is one of the main reasons it’s so easy to use. We have some more exciting developments on this front to share in the near future, so definitely stay tuned!

We are excited about our StartEngine investment momentum. 2023 will be our best year yet, thanks to your belief and support. We can't wait to keep growing and sharing our successes with you.

 

Best Regards,             

John Dinusson

President and CEO           

01.03.23

Happy New Year to our amazing Eva Medtec Early Bird Investor community!

A picture containing text

Description automatically generated

 

We are so excited to ring in the New Year with all of you! Your Early Bird investment will help us bring in an exciting New Year. In February 2023, our Medical Director, together with his team of lymphatic experts at UTHealth (The University of Texas) will conduct a NIR-FLI pilot study. This study will be the first to show video images of how lymphatic fluid moves in the back and neck before and after using the Neuroglide system. 

What makes Neuroglide stand out in the market is our focus on designing products that are FDA-cleared for safety and effectiveness. We deliver automated MLD therapy devices that truly help people who suffer from back and neck pain and poor circulation. 

We have received feedback from physicians who are recommending Neuroglide to their patients, and MLD therapists are purchasing Neuroglide for their physical medicine rehabilitation clinics. Many patients reported amazing decongestion of lymphatic stasis in their back and others reported sleeping better, less pain and less anxiety caused by pain. Please watch the LymphCast Episode #11, https://youtu.be/yLMUMVs8dE0 where our founder, Irene Waldridge, engages with lymphatic experts in a fascinating discussion about Neuroglide. 

Stay tuned for new developments including pilot study results and other user feedback stories coming up in 2023, and we can't wait to keep growing and sharing our successes with you:

 

 

Best Regards,                   

John Dinusson

President and CEO                                                                           

 

12.29.22

Happy Holidays to all Potential Investors!

I am excited to inform you Eva Medtec has raised a total of $3,948,095 of which $85,000 was raised in the last few days on StartEngine. This is strategically important for our continued success. We at Eva Medtec hope you will continue to support us by investing in our Super Early Bird round of fundraising via StartEngine.

For 2023, we will continue to scale up our commercialization of the NeuroglideTM System by bringing on our sales team to call on physicians and therapists. We also intend to conduct a NIRFLI imaging study in February with the intent to publish the results in March. We anticipate other studies additional publications. These studies will continue to validate the Neuroglide system and open new markets for our products.

 

Thank you for all your support and we appreciate your investment in Eva Medtec. We would not be where we without the valuable investments of our shareholders like you.

  

Best Regards,

 

John Dinusson

President and CEO

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Eva Medtec.

$299.00

Earn 10% Bonus Shares

Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.

$700.00

$700

Invest $700 and receive 2% bonus shares.

$1,500.00

$1,500+ | Tier 1

Invest $1,500 and receive 4% bonus shares.

$5,000.00

$5,000+ | Tier 2

Invest $5,000 and receive 7% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)

$10,000.00

$10,000+ | Tier 3

Invest $10,000 and receive 15% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)

$25,000.00

$25,000+ | Tier 4

Invest $25,000 and receive 20% bonus shares + a Neuroglide + 30-minute call with CEO or Founder (expert in Lymphedema & MLD)

JOIN THE DISCUSSION













0/2500

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$92,913.52
INVESTORS
31
MIN INVEST
$299.49
VALUATION
$11.03M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.